Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps
Dominique van Mil(University Medical Center Groningen), Ron T. Gansevoort, Hiddo J.L. Heerspink(University Medical Center Groningen), Xavier Pouwels(University of Twente)
Cited by 19
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990